Definitive Hypofractionated Simultaneous Integrated Boost Intensity-modulated Radiotherapy (60 Gy in 25 Fractions) in Elderly Patients with Locally Advanced Head and Neck Cancer Ineligible for Concurrent Chemotherapy: A Prospective, Single-arm Feasibility Study

A BSTRACT Background: Elderly patients with head and neck squamous cell carcinoma (HNSCC) often cannot tolerate prolonged conventional radiotherapy and are under-represented in trials. As the meta-analysis of chemotherapy in head and neck cancer meta-analysis shows the benefit of concurrent chemotherapy diminishes with age, radiotherapy alone is the appropriate backbone. We evaluated the feasibility of hypofractionated simultaneous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) delivering 60 Gy in 25 fractions over 5 weeks in chemotherapy-ineligible elderly HNSCC patients. Materials and Methods: Patients aged ≥70 years with locally advanced HNSCC, Eastern Cooperative Oncology Group 0–2, unfit for or declining concurrent chemotherapy received SIB-IMRT (60, 56, and 50 Gy in 25 fractions to high-, intermediate- and low-risk planning target volumes). The primary endpoint was feasibility (≥90% of planned dose within 35 days; Grade 4 acute toxicity <25%). Acute toxicity was graded by the RTOG criteria and response by RECIST v1.1. Late toxicity is not reported here.